BIOMARKER:

MSI-H/dMMR

MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: A1 - Approval NICE - 4 days
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	pembrolizumab Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	dostarlimab Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Peritoneal Cancer Peritoneal Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Small Intestinal Carcinoma Small Intestinal Carcinoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Colon Cancer Colon Cancer	CAPOX Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Colon Cancer Colon Cancer	FOLFOX Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Fallopian Tube Cancer Fallopian Tube Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Maxillary Sinus Carcinoma Maxillary Sinus Carcinoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Penile Cancer Penile Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Small Intestinal Carcinoma Small Intestinal Carcinoma	nivolumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Small Intestinal Carcinoma Small Intestinal Carcinoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Small Intestinal Carcinoma Small Intestinal Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Ovarian Cancer Ovarian Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Germ Cell Tumors Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab + ipilimumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Biliary Tract Cancer Biliary Tract Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Neuroendocrine Tumor Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Chordoma Chordoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Ewing Sarcoma Ewing Sarcoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Osteosarcoma Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Breast Cancer Breast Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Testicular Cancer Testicular Cancer	cemiplimab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Vulvar Cancer Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	KN035 Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	KN035 Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	KN035 Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	dostarlimab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Renal Cell Carcinoma RCC	dostarlimab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Gallbladder Cancer Gallbladder Cancer	dostarlimab Resistant: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Esophageal Cancer Esophageal Cancer	dostarlimab Resistant: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Breast Cancer Breast Cancer	dostarlimab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Ovarian Cancer Ovarian Cancer	dostarlimab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	dostarlimab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Uterine Cancer Uterine Cancer	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Gallbladder Cancer Gallbladder Cancer	pembrolizumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Prostate Cancer Prostate Cancer	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Cervical Cancer Cervical Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Glioblastoma GBM	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Gastrointestinal Cancer Gastrointestinal Cancer	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Gastrointestinal Cancer Gastrointestinal Cancer	pembrolizumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Urothelial Cancer Urothelial Cancer	nivolumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	INCMGA0012 Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	durvalumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	camrelizumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	regorafenib Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	XmAb717 Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	avelumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	CP-675206 Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	tislelizumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	BMS-986016 Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	tislelizumab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	sintilimab Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	HX008 Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	HLX10 Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	M7824 Resistant: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	bevacizumab Resistant: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	AZD1775 Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Prostate Cancer Prostate Cancer	PD1 inhibitor Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Prostate Cancer Prostate Cancer	paclitaxel + docetaxel + etoposide IV Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Biliary Tract Cancer Biliary Tract Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	PD-L1 inhibitor Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	PD1 inhibitor Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Prostate Cancer Prostate Cancer	pembrolizumab + BBI608 Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Prostate Cancer Prostate Cancer	pembrolizumab + enzalutamide Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab + TAS-116 Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab + maraviroc Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	sintilimab Sensitive: C3 – Early Trials

MSI-H/dMMR

Associations